About OneSource for aHUS Patients

About OneSource for aHUS Patients
5
(1)

If you have atypical hemolytic uremic syndrome (aHUS) and are being treated with Soliris (eculizumab) or Ultomiris (ravulizumab-cwvz), you may wish to consider enrolling in OneSource, a complimentary and personalized patient support program by Alexion, the therapies’ manufacturer.

What is aHUS?

aHUS is a rare multi-organ disorder marked by the formation of excessive blood clots. These clots can block small blood vessels, particularly those in the kidneys. Mutations that affect proteins of the complement system and environmental triggers typically cause aHUS.

The complement system is part of the immune system.

What is Soliris?

Soliris is a terminal complement inhibitor approved for use in children and adults. The humanized monoclonal antibody is an intravenous treatment, and works to stop blood clotting within small blood vessels.

What is Ultomiris?

Ultomiris is s also a humanized monoclonal antibody with a mechanism of action that’s similar to that of Soliris. The treatment, also administered directly into the bloodstream, works to stop clotting and is approved for use in children and adults.

What is OneSource?

OneSource is a free, tailored patient support program offered by Alexion, which developed Soliris and Ultomiris to treat aHUS. The program is for patients residing in the U.S. and Canada. A global access program may be available for people in other countries, Alexion reports.

If you or your child is receiving one of these treatments, registering with OneSource can give you access to nurse case managers who understand this disorder. Your case manager can provide personalized support regarding health insurance, disease information, and treatments.

How does OneSource work?

Once you enroll, you’re assigned a case manager. He or she will be your main contact with the program, and assist you throughout your treatment journey. All OneSource managers are registered nurses with extensive clinical experience. They have received specific training about resources and options available to patients.

Assistance with insurance

Managing a rare condition is challenging, and navigating the ins and outs of health insurance can be both tricky and overwhelming.

Your OneSource case manager can provide you with information to help you understand your insurance plan, and Soliris and Ultomiris coverage options. Your manager can also give you information about alternative funding options and resources if you have concerns with, or gaps in, your treatment coverage.

A co-pay program is also available for eligible patients with commercial health insurance coverage.

Information on your disease

OneSource case managers are knowledgeable about the rare diseases Alexion treats — in your case, aHUS. They will work with you to help you better understand this disorder.

Managers can provide you with educational materials, such as brochures, and other resources concerning aHUS. Whether you just received a diagnosis or have been living with aHUS for awhile, OneSource can help with disease and treatment information.

Ongoing support

Program managers aim to support you throughout your journey and all aspects of your life. For example, if your treatment location or insurance coverage changes, your manager will work with you and your doctor to facilitate a smooth transition.

If you’re moving house or planning a vacation and have concerns about treatment logistics, OneSource will remain available for help and support you along the way.

Community connection

When you have a rare disease, it’s easy to feel lonely. That’s why OneSource can also help patients plug into aHUS communities, and advocacy and support groups. The program can also keep you apprised of upcoming meetings and social events.

If you enroll in the program and wish to tell your story to motivate, assist or encourage others, there are opportunities to participate in the aHUS community.

How to start?

The interested need to complete the enrollment and authorization form, and download the informational brochure. For more information, contact [email protected], or by calling  1-888-765-4747.

 

Last updated: Feb. 22, 2021

***

aHUS News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”

Total Posts: 0
Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
×

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”

Latest Posts
  • Rare Disease Day project

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 1

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?